Nuformix Plc (NFX) AI Stock Analysis

• Market Cap: £6.12M
• Dividend Yield: N/A
• Average Volume (3M): 97.88M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.05
• Revenue Growth: N/A
• EPS Growth: -616.67%
• Country: UK
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 2,109,750,000
• 10 Day Avg. Volume: 69,476,590
• 30 Day Avg. Volume: 97,880,797
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.39
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: ―

Nuformix Plc's overall stock score reflects severe financial challenges, including a lack of revenue and persistent losses. While recent positive corporate developments and technical momentum offer some optimism, they are overshadowed by significant financial instability and negative valuation metrics.

Positive Factors

Orphan Drug Designation

The Orphan Drug Designation for NXP002 enhances market exclusivity and attractiveness to partners, potentially boosting long-term revenue and market position.

Partnership Opportunities

Engaging with potential partners for NXP002 could lead to strategic alliances, enhancing development capabilities and revenue potential through shared resources.

Shareholder Support

Strong shareholder support indicates confidence in management and strategic direction, providing stability and potential for future strategic initiatives.

Negative Factors

Lack of Revenue

The absence of revenue generation and continuous losses highlight financial instability, posing risks to sustainability and future growth prospects.

Negative Cash Flow

Ongoing negative cash flow challenges the company's ability to fund operations and investments, limiting growth and strategic flexibility.

Equity Erosion

Erosion of equity indicates financial stress, reducing the company's capacity to leverage for growth and impacting long-term financial health.

Nuformix Plc Business Overview & Revenue Model

Company Description

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

How the Company Makes Money

Nuformix Plc generates revenue through the development and licensing of its proprietary cocrystal technology to pharmaceutical partners. The company partners with other pharmaceutical organizations to co-develop drugs, sharing in the costs and revenues associated with these products. Additional revenue streams include milestone payments and royalties from successful commercialization of the drugs using their technology. Significant partnerships with larger pharmaceutical firms help in leveraging Nuformix's technology, providing a pathway to market for their innovations and contributing to its earnings.

Nuformix Plc Financial Statement Overview

Summary

Nuformix Plc faces significant financial difficulties marked by no revenue generation and persistent operational losses. While the balance sheet is not burdened by debt, the erosion of equity and negative cash flows present substantial risks. The company needs strategic financial improvements to stabilize and support future growth.

Income Statement

Nuformix Plc has struggled with generating revenue over the past years, with a notable absence of revenue in the most recent years. The company exhibits persistent net losses, with an EBIT margin that reflects significant operational challenges. The lack of revenue growth and negative profitability margins highlight financial instability.

Balance Sheet

The company's balance sheet shows a high proportion of equity relative to total assets, indicating a solid equity ratio. However, the continuous decrease in stockholders' equity and total assets over recent periods suggests potential financial stress. The absence of debt reduces financial risk but also reflects limited leverage for growth.

Cash Flow

Nuformix Plc's cash flow situation is concerning, with persistent negative free cash flow and operating cash flow over the years. The company has shown inconsistency in managing cash, with no substantial free cash flow growth. Operating cash flow ratios indicate challenges in converting earnings into actual cash inflows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	50.00K	195.55K	535.00K
Gross Profit	-14.58K	0.00	-36.75K	11.33K	86.72K	201.41K
EBITDA	-362.00	-477.19K	-581.90K	-1.23M	-1.28M	-832.90K
Net Income	-376.00	-3.64M	-572.98K	-1.11M	-1.25M	-756.38K
Balance Sheet
Total Assets	1.04M	970.54K	4.42M	4.98M	6.01M	5.13M
Cash, Cash Equivalents and Short-Term Investments	97.91K	20.21K	202.55K	464.10K	1.67M	543.77K
Total Debt	0.00	0.00	0.00	0.00	0.00	75.39K
Total Liabilities	229.52K	254.97K	222.99K	237.86K	324.62K	383.91K
Stockholders Equity	807.65K	715.57K	4.20M	4.74M	5.69M	4.74M
Cash Flow
Free Cash Flow	-391.00	-331.88K	-397.49K	-1.35M	-848.83K	-770.80K
Operating Cash Flow	-391.00	-331.88K	-397.49K	-1.35M	-848.22K	-727.60K
Investing Cash Flow	0.00	0.00	33.33K	0.00	43.72K	-43.20K
Financing Cash Flow	468.75K	149.54K	189.79K	139.98K	1.93M	1.31M

Nuformix Plc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.29
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:NFX, the sentiment is Positive. The current price of 0.29 is above the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.29, and above the 200-day MA of 0.17, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 52.39 is Neutral, neither overbought nor oversold. The STOCH value of 46.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:NFX.

Nuformix Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FUM	52 Neutral	£7.59M	-0.63	-115.97%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMM	46 Neutral	£36.70M	-8.20	-259.88%	―	―	―
TCF	45 Neutral	£4.51M	-1.62	-53.79%	―	―	85.56%
OPTI	43 Neutral	£6.09M	-42.14	-2.42%	―	―	―
HEMO	43 Neutral	£37.52M	-2.80	-609.30%	―	―	―
NFX	42 Neutral	£6.12M	-0.67	-153.80%	―	―	-616.67%

Nuformix Plc Corporate Events

Nuformix PLC Updates Total Voting Rights Following New Share Issuance

Nuformix PLC has announced the issuance of new ordinary shares, confirming its total voting rights as 2,109,749,903 shares, each carrying one voting right. This update aligns with the FCA’s Disclosure Guidance and Transparency Rules, providing shareholders with the necessary information to assess their interests in the company. This development is part of the company’s strategic financial management and may influence stakeholder decisions regarding shareholding notifications.

Nuformix Awaits FDA Response on Orphan Drug Designation for IPF Treatment

Nuformix plc has announced that the US FDA has requested further clarification on a specific element of its Orphan Drug Designation application for tranilast, part of its NXP002 programme targeting Idiopathic Pulmonary Fibrosis (IPF). The company plans to respond promptly using existing data, and remains optimistic about a successful outcome. Meanwhile, Nuformix is in discussions with potential licensing partners, indicating ongoing strategic efforts to advance its market position.

Nuformix plc Successfully Completes Oversubscribed Open Offer

Nuformix plc announced the results of its underwritten Open Offer, which closed on November 11, 2025. The offer was oversubscribed with valid acceptances for 465,813,047 shares, representing a take-up of approximately 408.5% of the available shares. The company will issue 114,040,535 shares, raising approximately £228,081 before expenses. This successful capital raise is expected to enhance Nuformix’s financial position and support its ongoing development efforts in the pharmaceutical sector.

Nuformix Launches £228,081 Open Offer to Advance Drug Repurposing Initiatives

Nuformix plc has announced an underwritten Open Offer to raise approximately £228,081 by issuing 114,040,535 Open Offer Shares at an Issue Price of 0.2p per share. This initiative is aimed at providing all Qualifying Shareholders the opportunity to participate, with CMC Markets UK Plc underwriting the offer. The funds are intended to support Nuformix’s strategy of developing new product opportunities in fibrosis and oncology, potentially enhancing its market position and offering significant value and early licensing opportunities.

Nuformix Appoints New Auditor Amid Strategic Developments

Nuformix plc has appointed Kreston Reeves Audit LLP as its new auditor following a restructuring of its former auditor, Kreston Reeves LLP. This change is pending shareholder approval at the company’s next Annual General Meeting. The appointment reflects Nuformix’s ongoing efforts to maintain robust financial oversight as it continues to pursue its strategic goals in the pharmaceutical development sector, potentially impacting its operational efficiency and stakeholder confidence.